Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HS-20094 versus dulaglutide in adults with type 2 diabetes mellitus inadequately controlled on metformin with or without an SGLT2 inhibitor
CTR20253482Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of olatorepatide in type 2 diabetes mellitus (T2DM), sponsored by Hengrui Therapeutics. Started Sep 2025; status: active.
02
Drugs
olatorepatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20253482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253482.